News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Meridica Extends Its Xcelodose(TM) Showcasing Agreement With Quintiles Inc. (QTRN)

10/19/2005 5:09:30 PM

CAMBRIDGE, UK, Dec. 12 /PRNewswire/ -- Meridica Limited, the Cambridge, UK-based drug delivery company, today announced the renewal of its Showcasing Agreement for Xcelodose(TM), its unique powder micro-dosing technology, with Quintiles, the world's leading pharmaceutical services organisation.

The Showcasing Agreement, which has already been in place for over a year, makes an Xcelodose(TM) system available to Quintiles' customers in Quintiles' GMP facilities at Edinburgh, UK, as well as providing the framework for co- promotion of the Xcelodose(TM) technology to the pharmaceutical industry.

Quintiles currently features Xcelodose(TM) as a unique technology, which has enabled the company to offer its customers micro-dosing of pharmaceutical drug powder for use in oral dose and inhaled dose clinical supplies. The Xcelodose(TM) technology has a number of substantial business benefits, including potentially shortening the drug development process, by reducing the need for costly stability studies, and the avoidance of laborious hand-filling of capsules.

Dr. Phil Woodhead, Quintiles' VP Pharmaceutical Sciences Europe, said, "The successful Showcasing Agreement with Meridica has enabled us to offer the innovative Xcelodose(TM) technology to the marketplace. This has clearly fulfilled an unmet market need as, since its installation in May 2002, it has been in constant demand by pharmaceutical companies. We are pleased to extend this Agreement with Meridica and our investment in the Xcelodose(TM) system serves to reinforce Quintiles' commitment to providing innovative technologies to its clients."

David Edwards, Meridica's Director of Strategic Marketing, said, "As the world's largest pharmaceutical services organisation, Quintiles provides a major endorsement of the value of our Xcelodose(TM) technology to the pharmaceutical industry. We are delighted to continue our relationship, which we believe has been mutually beneficial. We believe the relationship has worked extremely well at all levels between Meridica and Quintiles and look forward to continuing success in developing this market."


Meridica is a drug delivery company specialising in the development of creative solutions for inhaled, nasal and parenteral routes of administration. In addition to Xcelodose(TM), its unique micro-dosing system for dispensing drug powders, it has developed a novel multi-unit dose dry powder inhaler, Xcelovair(TM), for the delivery of drugs to the lung for the treatment of asthma, COPD and other respiratory conditions. Meridica is a PA Group Company and is based in Cambridge, UK.

Quintiles helps improve healthcare worldwide by providing a broad range of professional services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. Headquartered near Research Triangle Park, North Carolina, and with offices in more than 40 countries, Quintiles is a leading global pharmaceutical services organization and a member of the Fortune 1000. For more information visit the company's Web site at

PA Consulting Group is a leading management, systems and technology consulting firm, with a unique combination of these capabilities. Established almost 60 years ago, and operating worldwide from over 40 offices in more than 20 countries, PA draws on the knowledge and experience of some 3,300 people, whose skills span the initial generation of ideas and insights all the way through to detailed implementation.

For more information, visit the web site at Contact: David Edwards, Director of Strategic Marketing Meridica Ltd., Cambridge Technology Centre, Melbourn, Herts, SG8 6DQ, UK Tel +44 1763 261 600 Contact: Charlotte Taylor, Quintiles Media Relations ( +44 1344 708 386

Meridica Ltd.

CONTACT: David Edwards, Director of Strategic Marketing, of MeridicaLimited,, or Charlotte Taylor of Quintiles, MediaRelations, +44 1344 708 386, or

Read at

comments powered by Disqus